J. Blokken PhD, PharmD

Journal scan

SUMMARY

In this section of the Belgian Journal of Hematology (BJH), we aim to provide a snapshot of pivotal studies published in recent issues of the most important international journals focusing on haematology. Importantly, the selection of the studies discussed here is the sole responsibility of the publisher and was not influenced by third parties. Do you miss an important study, or did you read a hidden jewel that deserves to be shared with your colleagues? Please, let us know (editor@bjh.be) and we will make sure to include it in the journal scan section of the next BJH issue.

(BELG J HEMATOL 2022;13(6):256–9)

Highlights in multiple myeloma

SUMMARY

During the past European Hematology Association’s annual congress (EHA 2022), four oral sessions were devoted to clinical trials and recent advances in myeloma. These sessions covered newly diagnosed multiple myeloma (MM), antibody-based therapy in relapsed/refractory (RR) MM, BCMA-directed treatment in RRMM and biology and translational research. Below, we summarise the highlights from some of the studies that were presented in each of these sessions.

(BELG J HEMATOL 2022;13(5):219–23)

Journal scan

SUMMARY

In this section of the Belgian Journal of Hematology (BJH), we aim to provide a snapshot of pivotal studies published in recent issues of the most important international journals focusing on haematology. Importantly, the selection of the studies discussed here is the sole responsibility of the publisher and was not influenced by third parties. Do you miss an important study, or did you read a hidden jewel that deserves to be shared with your colleagues? Please, let us know (editor@bjh.be) and we will make sure to include it in the journal scan section of the next BJH issue.

(BELG J HEMATOL 2022;13(4):175–8)

Journal scan

SUMMARY

In this section of the Belgian Journal of Hematology (BJH), we aim to provide a snapshot of pivotal studies published in recent issues of the most important international journals focusing on haematology. Importantly, the selection of the studies discussed here is the sole responsibility of the publisher and was not influenced by third parties. Do you miss an important study, or did you read a hidden jewel that deserves to be shared with your colleagues? Please, let us know (editor@bjh.be) and we will make sure to include it in the journal scan section of the next BJH issue.

(BELG J HEMATOL 2022;13(3):137–40)

Journal scan

In this section of the BJH, we aim to provide a snapshot of pivotal studies published in recent issues of the most important international journals focusing on haematology. Importantly, the selection of the studies discussed here is the sole responsibility of the publisher and was not influenced by third parties. Do you miss an important study, or did you read a hidden jewel that deserves to be shared with your colleagues? Please, let us know (editor@bjh.be) and we will make sure to include it in the journal scan section of the next BJH issue.

(BELG J HEMATOL 2022;13(2):101–3)

Advances in laboratory technology

In recent years, we have witnessed many advances in laboratory technology to detect germline or somatic mutations that predispose individuals to the development of haematopoietic malignancies. The laboratory technology session during the BHS GAM kicked off with a presentation from Dr. Ann Debecker explaining the differences between CHIP, CHOP and ARCH. In a second lecture of the laboratory technology session, Dr. Ine Moors provided a contemporary overview on genetic predisposition for myeloid malignancies.

Joint BeSHG-BHS meeting

The Belgian Society of Human Genetics (BeSHG) was launched in March 2000 and aims at promoting human genetics in its wider sense, i.e. by supporting genetic research, improving exchanges between Belgium and foreign countries, organising scientific meetings, and enhancing collaboration between Belgian labs. During the 37th general annual meeting of the Belgian Haematology Society, a joint BeSHG-BHS session was organised. In this session, Karlijn Brekelmans (University Hospital Leuven, Leuven, Belgium) first discussed how genetic predisposition in haemato-oncological disorders can be detected, with a focus on technique, type of tissue that can be used and turn-around-time. Her talk was followed by a presentation from Esmé Waanders (Princess Maxima Centre, Utrecht, The Netherlands) discussing geentic predisposition in lymphoid malignancies.